Truist raises Pacira stock to buy, price target to $25 from $8
Truist Securities upgraded Pacira Pharmaceuticals (NASDAQ:PCRX) stock rating from Hold to Buy, significantly raising the price target to $25.00 from the previous $8.00. The stock, currently trading at ...